Advertisement

Tumor Biology

, Volume 35, Issue 10, pp 9999–10009 | Cite as

Altered expression of apoptotic genes in response to OCT4B1 suppression in human tumor cell lines

  • Mohammad Reza Mirzaei
  • Ali Najafi
  • Mohammad Kazemi Arababadi
  • Malek Hosein Asadi
  • Seyed Javad Mowla
Research Article

Abstract

OCT4B1 is a newly discovered spliced variant of OCT4 which is primarily expressed in pluripotent and tumor cells. Based on our previous studies, OCT4B1 is significantly overexpressed in tumors, where it endows an anti-apoptotic property to tumor cells. However, the mechanism by which OCT4B1 regulates the apoptotic pathway is not yet elucidated. Here, we investigated the effects of OCT4B1 suppression on the expression alteration of 84 genes involved in apoptotic pathway. The AGS (gastric adenocarcinoma), 5637 (bladder tumor), and U-87MG (brain tumor) cell lines were transfected with OCT4B1 or irrelevant siRNAs. The expression level of apoptotic genes was then quantified using a human apoptosis panel-PCR kit. Our data revealed an almost similar pattern of alteration in the expression profile of apoptotic genes in all three studied cell lines, following OCT4B1 suppression. In general, the expression of more than 54 apoptotic genes (64 % of arrayed genes) showed significant changes. Among these, some up-regulated (CIDEA, CIDEB, TNFRSF1A, TNFRSF21, TNFRSF11B, TNFRSF10B, and CASP7) and down-regulated (BCL2, BCL2L11, TP73, TP53, BAD, TRAF3, TRAF2, BRAF, BNIP3L, BFAR, and BAX) genes had on average more than tenfold gene expression alteration in all three examined cell lines. With some minor exceptions, suppression of OCT4B1 caused upregulation of pro-apoptotic and down-regulation of anti-apoptotic genes in transfected tumor cells. Uncovering OCT4B1 down-stream targets could further elucidate its part in tumorigenesis, and could lead to finding a new approach to combat cancer, based on targeting OCT4B1.

Keywords

OCT4B1 siRNA Apoptosis pathway CIDEA TNFRSF21 

Notes

Acknowledgments

This project was financially supported by research grants from the Rafsanjan University of Medical Sciences, and research deputy of Tarbiat Modares University.

References

  1. 1.
    Rosner MH, Vigano MA, Ozato K, Timmons PM, Poirier F, Rigby PW, et al. A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature. 1990;345:686–92.CrossRefPubMedGoogle Scholar
  2. 2.
    Gazouli M, Roubelakis MG, Theodoropoulos GE, Papailiou J, Vaiopoulou A, Pappa KI, et al. OCT4 spliced variant OCT4B1 is expressed in human colorectal cancer. Mol Carcinog. 2012;51:165–73.CrossRefPubMedGoogle Scholar
  3. 3.
    Navarro P, Festuccia N, Colby D, Gagliardi A, Mullin NP, Zhang W, et al. OCT4/SOX2-independent Nanog auto repression modulates heterogeneous Nanog gene expression in mouse ES cells. The EMBO J. 2012;31:4547–62.CrossRefPubMedGoogle Scholar
  4. 4.
    Chen Z, Xu WR, Qian H, Zhu W, Bu XF, Wang S, et al. Oct4, a novel marker for human gastric cancer. J Surg Oncol. 2009;99:414–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Suo G, Han J, Wang X, Zhang J, Zhao Y, Dai J. Oct4 pseudogenes are transcribed in cancers. Biochem Biophys Res Commun. 2005;337:1047–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Wang Y, Meng L, Hu H, Zhang Y, Zhao C, Li Q, et al. Oct-4B isoform is differentially expressed in breast cancer cells: hypermethylation of regulatory elements of Oct-4A suggests an alternative promoter and transcriptional start site for Oct-4B transcription. Biosci Rep. 2011;31:109–15.CrossRefPubMedGoogle Scholar
  7. 7.
    Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer. 2007;120:1598–602.CrossRefPubMedGoogle Scholar
  8. 8.
    Farashahi Yazd E, Rafiee MR, Soleimani M, Tavallaei M, Salmani MK, Mowla SJ. OCT4B1, a novel spliced variant of OCT4, generates a stable truncated protein with a potential role in stress response. Cancer Lett. 2011;309:170–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Atlasi Y, Mowla SJ, Ziaee SA, Gokhale PJ, Andrews PW. OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. Stem Cells. 2008;26:3068–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Asadi MH, Mowla SJ, Fathi F, Aleyasin A, Asadzadeh J, Atlasi Y. OCT4B1, a novel spliced variant of OCT4, is highly expressed in gastric cancer and acts as an antiapoptotic factor. Int J Cancer. 2011;128:2645–52.CrossRefPubMedGoogle Scholar
  11. 11.
    Papamichos SI, Kotoula V, Tarlatzis BC, Agorastos T, Papazisis K, Lambropoulos AF. OCT4B1 isoform: the novel OCT4 alternative spliced variant as a putative marker of stemness. Mol Hum Reprod. 2009;15:269–70.CrossRefPubMedGoogle Scholar
  12. 12.
    Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev in Clin Lab Sci. 2006;43:1–67.CrossRefGoogle Scholar
  13. 13.
    Crnkovic-Mertens I, Hoppe-Seyler F, Butz K. Induction of apoptosis in tumor cells by siRNA-mediated silencing of the living/ML-IAP/KIAP gene. Oncogene. 2003;22:8330–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277–88.CrossRefPubMedGoogle Scholar
  15. 15.
    Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994;73:2013–26.CrossRefPubMedGoogle Scholar
  16. 16.
    Yu M, Wang H, Zhao J, Yuan Y, Wang C, Li J, et al. Expression of CIDE proteins in clear cell renal cell carcinoma and their prognostic significance. Mol Cell Biochem. 2013;378:145–51.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Inohara N, Koseki T, Chen S, Wu X, Nunez G. CIDE, a novel family of cell death activators with homology to the 45 kDa subunit of the DNA fragmentation factor. The EMBO J. 1998;17:2526–33.CrossRefPubMedGoogle Scholar
  18. 18.
    Pan G, Bauer JH, Haridas V, Wang S, Liu D, Yu G, et al. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett. 1998;431:351–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Marik SA, Olsen O, Tessier-Lavigne M, Gilbert CD. Death receptor 6 regulates adult experience-dependent cortical plasticity. J Neurosci. 2013;33:14998–5003.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415–20.PubMedGoogle Scholar
  21. 21.
    Asadzadeh J, Asadi MH, Shakhssalim N, Rafiee MR, Kalhor HR, Tavallaei M, et al. A plausible anti-apoptotic role of up-regulated OCT4B1 in bladder tumors. Urol J. 2012;9:574–80.PubMedGoogle Scholar
  22. 22.
    Benschop R, Wei T, Na S. Tumor necrosis factor receptor superfamily member 21: TNFR-related death receptor-6, DR6. Adv Exp Med Biol. 2009;647:186–94.CrossRefPubMedGoogle Scholar
  23. 23.
    Belizario JE, Alves J, Garay-Malpartida M, Occhiucci JM. Coupling caspase cleavage and proteasomal degradation of proteins carrying PEST motif. Curr Protein & Pept Sci. 2008;9:210–20.CrossRefGoogle Scholar
  24. 24.
    Vaculova A, Zhivotovsky B. Caspases: determination of their activities in apoptotic cells. Methods Enzymol. 2008;442:157–81.CrossRefPubMedGoogle Scholar
  25. 25.
    Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996;10:456–9.PubMedGoogle Scholar
  26. 26.
    Guo Y, Karube K, Kawano R, Suzumiya J, Takeshita M, Kikuchi M, et al. Bcl2-negative follicular lymphomas frequently have Bcl6 translocation and/or Bcl6 or p53 expression. Pathol Int. 2007;57:148–52.CrossRefPubMedGoogle Scholar
  27. 27.
    Gil J, Garcia MA, Gomez-Puertas P, Guerra S, Rullas J, Nakano H, et al. TRAF family proteins link PKR with NF-?B activation. Mol Cell Biol. 2004;24(10):4502–12.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Carpentier I, Beyaert R. TRAF1 is a TNF inducible regulator of NF-kappaB activation. FEBS Lett. 1999;460:246–50.CrossRefPubMedGoogle Scholar
  29. 29.
    Darding M, Meier P. IAPs: guardians of RIPK1. Cell Death Differ. 2012;19:58–66.CrossRefPubMedGoogle Scholar
  30. 30.
    Wang Y, Tang X, Yu B, Gu Y, Yuan Y, Yao D, et al. Gene network revealed involvements of Birc2, Birc3 and Tnfrsf1a in anti-apoptosis of injured peripheral nerves. PLoS One. 2012;7:e43436.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene. 2008;27:6207–15.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Mohammad Reza Mirzaei
    • 1
  • Ali Najafi
    • 2
  • Mohammad Kazemi Arababadi
    • 3
  • Malek Hosein Asadi
    • 4
  • Seyed Javad Mowla
    • 1
  1. 1.Department of Molecular Genetics, Faculty of Biological SciencesTarbiat Modares UniversityTehranIran
  2. 2.Molecular Biology Research CenterBaqiyatallah University of Medical SciencesTehranIran
  3. 3.Immunology of Infectious Diseases Research CenterRafsanjan University of Medical SciencesRafsanjanIran
  4. 4.Department of Biotechnology, Institute of Science and High Technology and Environmental SciencesGraduate University of Advanced TechnologyKermanIran

Personalised recommendations